Editing the Human Genome
By BBC Newshour Extra,
BBC Newshour Extra
| 11. 28. 2015
Remarkable new techniques for ‘editing’ DNA – chemically cutting and splicing sections of genetic code – are revolutionising research in laboratories around the world. The potential for eradicating hereditary diseases is enormous. But are the benefits outweighed by the risks involved? And should these techniques ever be used on humans? On Newshour Extra this week, Owen Bennett Jones and his panel of expert guests discuss the scientific and ethical consequences of this latest research, and ask whether mankind should be tinkering with our genetic inheritance.
Contributors: Prof Robin Lovell-Badge - Head of Stem Cell Biology and Developmental Genetics at the Francis Crick Institute; Michael Le Page -New Scientist magazine; Dr Annelien Bredenoord - Associate Professor of Biomedical Ethics at the University Medical Centre in Utrecht; Marcy Darnovsky - Executive Director of the Center for Genetics and Society, Berkeley, California; James Rushbrooke - playwrite; Edward Perello - co-founder of Desktop Genetics
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
